SC
BCRX icon

Stephens Consulting’s BioCryst Pharmaceuticals BCRX Stock Holding History

Stephens Consulting’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50
Closed -$375 – 1293
2025
Q1 		$375 Buy
+50
New +$403 ﹤0.01% 1162

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Stephens Consulting's BCRX Position: Q2 2025 in Review

Stephens Consulting sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2025, closing a stake of 50 shares — an estimated $375 sold.

Stephens Consulting first reported a position in BCRX in Q1 2025 and held it in 1 quarter. The position peaked at $375 in Q1 2025. 294 funds tracked by Wall St. Rank hold BCRX as of Q2 2025.

  • Stephens Consulting reported no remaining BioCryst Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 50 BioCryst Pharmaceuticals shares in Q2 2025, an estimated $375.
  • Stephens Consulting first reported a position in BioCryst Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's BioCryst Pharmaceuticals position peaked at $375 in Q1 2025.
  • 294 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.